Newly-released Intravenous Iron Drugs market analysis report by Future Market Insights shows that global sales of the Intravenous Iron Drugs Market in 2021 were held at US$ 2.6 billion. With 8.5%, the projected market growth from 2022 to 2032 is expected to be higher than the historical growth.
The Intravenous Iron Drugs Market is projected to witness an absolute dollar opportunity of US$ 3.5 billion. The prevalence of chronic kidney disease (CKD), Inflammatory Bowel Disease (IBD), and cancer have increased the demand for intravenous iron medicines for the treatment of subsequent Iron Deficiency Anaemia.
| Attribute | Details |
|---|---|
| Global Intravenous Iron Drugs Market (2022) | US$ 2.8 billion |
| Global Intravenous Iron Drugs Market (2032) | US$ 6.3 billion |
| Global Intravenous Iron Drugs Market CAGR (2022 to 2032) | 8.5% |
| USA Intravenous Iron Drugs Market (2022) | US$ 922.7 million |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Intravenous Iron Drugs market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Intravenous Iron Drugs Market increased at around 8.1% CAGR, wherein, the region North America held a significant share in the global market.
Iron is a component of haemoglobin, which transports oxygen in the blood and also allows for the creation of red blood cells. Anaemia is a diagnosed condition in which an individual is lacking in the body's iron needs. Anaemia symptoms include weariness and loss of energy, unusually quick heartbeat when exercising, difficulties concentrating, pale skin and dizziness, sleeplessness, and cramping.
According to a recent survey done by the Vitamin and Mineral Nutrition Information System (VMNIS), around 40% of mothers and children in poor nations are anaemic. As a result, the market is expected to grow at a CAGR of 8.5% over the next ten years.
Anaemia is one of the most frequent blood illnesses nowadays. Anaemia affects an estimated 3 million people in the United States, according to the National Heart, Lung, and Blood Institute. The rising incidence of target illnesses such as rheumatoid arthritis, autoimmune diseases, renal issues, cancer, liver disorders, thyroid diseases, and inflammatory bowel disease is a significant factor driving the expansion of the intravenous iron medication market.
As per National Kidney Foundation, the two primary causes of CKD are diabetes and hypertension. Also, according to the report, the chronic renal disease affects approximately 10% of the worldwide population, with over 2 million people needing dialysis on a daily basis. The bulk of all these people is often observed in nations such as Italy, the United States, Germany, Japan, and Brazil.
A significant number of people who have the disease are unaware of it until severe symptoms appear. The frequency of chronic kidney disease is expected to rise in developing economies such as India and China, implying an increase in the elderly population in the future years. With the increasing incidence of these disorders, there is a greater demand for intravenous iron medicines.
One of the biggest disadvantages of oral iron medications is the possibility of significant side effects. Digestive issues such as stomach pains, constipation, lack of appetite, nausea, and vomiting are common side effects of oral iron medications. Convulsions, shallow or quick breathing, exhaustion or weakness, fatigue, pale complexion, and bluish skin or fingernails can all result from an overdose of oral iron medications.
Intravenous iron medications, on the other hand, have been demonstrated to promote iron intake by the body, allowing Erythropoiesis-stimulating Agents (ESAs) to act more effectively in lowering anemic conditions. Other benefits of intravenous iron medications include heart health preservation and the potential to be utilized by dialysis patients, particularly those undergoing hemodialysis. These negative effects are thus expected to assist the changeover to intravenous iron medications, boosting their use during the projection period.
Principal Consultant
The market in Asia Pacific is expected to swell at a significant pace of 8.6% from 2022 to 2032. This may be ascribed to the availability of prominent players in the Asia Pacific, as well as the strengthening of healthcare infrastructure with the growing government efforts. Furthermore, the prevalence of IDA in rising economies such as China and India has aided industry expansion.
Besides, the market in Europe is anticipated to increase significantly throughout the forecast year as a result of the growing research and commercialization of new products, the acceptance of advanced medications, and the region's rising incidence of malignancy.
The United States dominated the North American Intravenous Iron Drugs Market, which is expected to reach US$ 2.2 billion by 2032 and will increase at a CAGR of 9.3% CAGR during the forecast period. The reimbursement and technological advancement facilities are advantageous factors for market growth in the United States.
The growing geriatric population is a key driver of market expansion in the country. According to USA Census Bureau projections, the number of Americans aged 65 and up is expected to grow from 52 million in 2018 to nearly 95 million by 2060. Furthermore, the share of people aged 65 and up is expected to rise from 16% to 23%.
Its dominance is also due to the region's rising rates of cancer, chronic renal disease, and gastrointestinal ailments. Furthermore, an increase in awareness of women's health and a surge in the frequency of celiac disease are the other factors boosting the market in the country.
The market for intravenous iron drugs in the United Kingdom stood at US$ 115 million in 2021. The market in the country is projected to swell at a CAGR of 8.2% during the forecast period to reach a valuation of US$ 278 million by 2032. The market in the country is expected to register an absolute dollar opportunity of US$ 151 million from 2022 to 2032.
The market in Japan is likely to expand with an absolute dollar opportunity of US$ 128 million from 2022 to 2032. The market in the country is expected to reach a valuation of US$ 233 million by 2032 growing at a CAGR of 8.2% during the forecast period.
In South Korea, the market is projected to reach a valuation of US$ 127 million by 2032, growing from US$ 66 million in 2022. With an absolute dollar opportunity of US$ 61 million, the market in the country is expected to register a CAGR of 6.7% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In 2020, the market for intravenous iron drugs led the market for intravenous medicines for chronic kidney disease, accounting for 30% of the total in 2021. This large market may be due to the fact that chronic kidney disease (CKD) and intravenous iron therapies are intensively used by CKD patients. IDA is a prevalent complication in CKD patients. It is uncommon in the early stages of renal illness; nevertheless, it happens as the disease progresses and kidney function declines.
Anaemia is caused by a decrease in the amount of Red Blood Cells (RBCs) in CKD patients. The growth in CKD cases has resulted in a large increase in the number of IDA patients. The conventional therapy for people with dialysis and non-dialysis-related CKD is intravenous iron. Dialysis is used to treat anaemia and end-stage renal failure.
Due to the increasing incidence of cancer and the consequent increase in the number of IDA cases, the market revenue through cancer application is expected to grow at the fastest CAGR throughout the projection period.
IDA affects a considerable proportion of cancer patients. Blood cancer, bone cancer, cervical cancer, colon cancer, and prostate cancer are all common cancers associated with anaemia. According to the NCBI, lung and breast cancers have the highest rate of anaemia among solid tumours. Hematologic cancers, such as leukaemia, lymphoma, and multiple myeloma, create abnormal blood cells, which weaken the immune system and cause anaemia. Chemotherapy and radiation therapy are two cancer therapies that cause anaemia in individuals.
Some of the key players in the global Intravenous Iron Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; and Shield Therapeutics Plc among others.
Some of the recent developments in the Intravenous Iron Drugs Market are:
The global market is worth more than US$ 2.6 billion at present.
The value of the Intravenous Iron Drugs Market is projected to increase at a CAGR of around 8.5% from 2022 to 2032.
The value of the Intravenous Iron Drugs Market increased at a CAGR of around 8.1% from 2017 to 2021.
The top 5 countries driving demand for the Intravenous Iron Drugs market are the USA, China, the United Kingdom, Japan, and South Korea.
The USA market for Intravenous Iron Drugs is projected to expand at a CAGR of around 9.3% from 2022 to 2032.
The key companies in intravenous iron drugs market are AMAG Pharmaceuticals, AbbVie Inc., Daiichi Sankyo Company Ltd., Sanofi, and Vifor Pharma Management Ltd.
1. Executive Summary | Intravenous Iron Drugs Market
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ million)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background and Foundation Data Points
4.1. Global Market (US$ million)
4.2. Market Opportunity Assessment (US$ million)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Global Market Growth
4.5.3. Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032
6.1. Historical Market Analysis, 2017 to 2021
6.2. Current and Future Market Projections, 2022 to 2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ million) Analysis, 2017 to 2021
7.2. Current and Future Market Value (US$ million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Analysis By Product Type, 2017 to 2021
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Product Type, 2022 to 2032
8.3.1. Iron Dextran
8.3.2. Iron Sucrose
8.3.3. Ferric carboxymaltose
8.3.4. Other Product Types
8.4. Market Attractiveness Analysis By Product Type
9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) Analysis By Indication, 2017 to 2021
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Indication, 2022 to 2032
9.3.1. Chronic Kidney Disease
9.3.2. Inflammatory Bowel Disease
9.3.3. Cancer
9.3.4. Other Applications
9.4. Market Attractiveness Analysis By Indication
10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
10.1. Introduction
10.2. Historical Market Size (US$ million) Analysis By Region, 2017 to 2021
10.3. Current Market Size (US$ million) & Analysis and Forecast By Region, 2022 to 2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
11.1. Introduction
11.2. Pricing Analysis
11.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
11.4.1. By Country
11.4.1.1. The USA
11.4.1.2. Canada
11.4.1.3. Rest of North America
11.4.2. By Product Type
11.4.3. By Indication
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Product Type
11.5.3. By Indication
12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
12.4.1. By Country
12.4.1.1. Brazil
12.4.1.2. Mexico
12.4.1.3. Rest of Latin America
12.4.2. By Product Type
12.4.3. By Indication
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Product Type
12.5.3. By Indication
13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
13.4.1. By Country
13.4.1.1. Germany
13.4.1.2. France
13.4.1.3. The United Kingdom
13.4.1.4. Italy
13.4.1.5. Benelux
13.4.1.6. Nordic Countries
13.4.1.7. Rest of Europe
13.4.2. By Product Type
13.4.3. By Indication
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Product Type
13.5.3. By Indication
14. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
14.4.1. By Country
14.4.1.1. China
14.4.1.2. Japan
14.4.1.3. South Korea
14.4.1.4. Rest of Asia Pacific
14.4.2. By Product Type
14.4.3. By Indication
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Product Type
14.5.3. By Indication
15. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032
15.4.1. By Country
15.4.1.1. GCC Countries
15.4.1.2. South Africa
15.4.1.3. Turkey
15.4.1.4. Rest of Middle East and Africa
15.4.2. By Product Type
15.4.3. By Indication
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Product Type
15.5.3. By Indication
16. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.1.1. Market Value Proportion Analysis, By Key Countries
16.1.2. Global Vs. Country Growth Comparison
16.2. US Market Analysis
16.2.1. Value Proportion Analysis by Market Taxonomy
16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.2.2.1. By Product Type
16.2.2.2. By Indication
16.3. Canada Market Analysis
16.3.1. Value Proportion Analysis by Market Taxonomy
16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.3.2.1. By Product Type
16.3.2.2. By Indication
16.4. Mexico Market Analysis
16.4.1. Value Proportion Analysis by Market Taxonomy
16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.4.2.1. By Product Type
16.4.2.2. By Indication
16.5. Brazil Market Analysis
16.5.1. Value Proportion Analysis by Market Taxonomy
16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.5.2.1. By Product Type
16.5.2.2. By Indication
16.6. Germany Market Analysis
16.6.1. Value Proportion Analysis by Market Taxonomy
16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.6.2.1. By Product Type
16.6.2.2. By Indication
16.7. France Market Analysis
16.7.1. Value Proportion Analysis by Market Taxonomy
16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.7.2.1. By Product Type
16.7.2.2. By Indication
16.8. Italy Market Analysis
16.8.1. Value Proportion Analysis by Market Taxonomy
16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.8.2.1. By Product Type
16.8.2.2. By Indication
16.9. BENELUX Market Analysis
16.9.1. Value Proportion Analysis by Market Taxonomy
16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.9.2.1. By Product Type
16.9.2.2. By Indication
16.10. The United Kingdom Market Analysis
16.10.1. Value Proportion Analysis by Market Taxonomy
16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.10.2.1. By Product Type
16.10.2.2. By Indication
16.11. Nordic Countries Market Analysis
16.11.1. Value Proportion Analysis by Market Taxonomy
16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.11.2.1. By Product Type
16.11.2.2. By Indication
16.12. China Market Analysis
16.12.1. Value Proportion Analysis by Market Taxonomy
16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.12.2.1. By Product Type
16.12.2.2. By Indication
16.13. Japan Market Analysis
16.13.1. Value Proportion Analysis by Market Taxonomy
16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.13.2.1. By Product Type
16.13.2.2. By Indication
16.14. South Korea Market Analysis
16.14.1. Value Proportion Analysis by Market Taxonomy
16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.14.2.1. By Product Type
16.14.2.2. By Indication
16.15. GCC Countries Market Analysis
16.15.1. Value Proportion Analysis by Market Taxonomy
16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.15.2.1. By Product Type
16.15.2.2. By Indication
16.16. South Africa Market Analysis
16.16.1. Value Proportion Analysis by Market Taxonomy
16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.16.2.1. By Product Type
16.16.2.2. By Indication
16.17. Turkey Market Analysis
16.17.1. Value Proportion Analysis by Market Taxonomy
16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032
16.17.2.1. By Product Type
16.17.2.2. By Indication
16.17.3. Competition Landscape and Player Concentration in the Country
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Concentration
17.3. Market Share Analysis of Top Players
17.4. Market Presence Analysis
17.4.1. By Regional footprint of Players
17.4.2. Product footprint by Players
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. VIFOR PHARMA MANAGEMENT LTD.
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Sales Footprint
18.3.1.4. Strategy Overview
18.3.2. AMAG PHARMACEUTICALS
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Sales Footprint
18.3.2.4. Strategy Overview
18.3.3. DAIICHI SANKYO COMPANY, LTD.
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Sales Footprint
18.3.3.4. Strategy Overview
18.3.4. SANOFI S.A.
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Sales Footprint
18.3.4.4. Strategy Overview
18.3.5. PHARMACOSMOS A/S
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Sales Footprint
18.3.5.4. Strategy Overview
18.3.6. SHIELD THERAPEUTICS PLC
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Sales Footprint
18.3.6.4. Strategy Overview
18.3.7. ABBVIE INC.
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Sales Footprint
18.3.7.4. Strategy Overview
19. Assumptions and Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Intravenous Iron Drugs Market
